197 related articles for article (PubMed ID: 21917756)
21. FLT3-TKD Mutations Associated With NPM1 Mutations Define a Favorable-risk Group in Patients With Acute Myeloid Leukemia.
Perry M; Bertoli S; Rocher C; Hayette S; Ducastelle S; Barraco F; Labussière-Wallet H; Salles G; Recher C; Thomas X; Paubelle E
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e545-e550. PubMed ID: 30082225
[TBL] [Abstract][Full Text] [Related]
22. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).
Falini B; Macijewski K; Weiss T; Bacher U; Schnittger S; Kern W; Kohlmann A; Klein HU; Vignetti M; Piciocchi A; Fazi P; Martelli MP; Vitale A; Pileri S; Miesner M; Santucci A; Haferlach C; Mandelli F; Haferlach T
Blood; 2010 May; 115(18):3776-86. PubMed ID: 20203266
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
24. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
25. [Clinical characteristics of newly diagnosed acute myeloid leukemia patients with NPM1 mutation].
Wei H; Zhang YQ; Lin D; Wang Y; Zhou CL; Liu BC; Li W; Rao Q; Wang M; Mi YC; Wang JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):11-5. PubMed ID: 24598642
[TBL] [Abstract][Full Text] [Related]
26. Acute myeloid leukemia in patients older than 75: prognostic impact of FLT3-ITD and NPM1 mutations.
Hirsch P; Qassa G; Marzac C; Tang R; Perrot JY; Isnard F; Mohty M; Marie JP; Legrand O
Leuk Lymphoma; 2015 Jan; 56(1):147-50. PubMed ID: 24724782
[TBL] [Abstract][Full Text] [Related]
27. FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India.
Ghosh K; Swaminathan S; Madkaikar M; Gupta M; Kerketta L; Vundinti B
Ann Hematol; 2012 Nov; 91(11):1703-12. PubMed ID: 22733614
[TBL] [Abstract][Full Text] [Related]
28. Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.
Shimada A; Iijima-Yamashita Y; Tawa A; Tomizawa D; Yamada M; Norio S; Watanabe T; Taga T; Iwamoto S; Terui K; Moritake H; Kinoshita A; Takahashi H; Nakayama H; Koh K; Goto H; Kosaka Y; Saito AM; Kiyokawa N; Horibe K; Hara Y; Oki K; Hayashi Y; Tanaka S; Adachi S
Int J Hematol; 2018 May; 107(5):586-595. PubMed ID: 29330746
[TBL] [Abstract][Full Text] [Related]
29. Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.
de Jonge HJ; Valk PJ; de Bont ES; Schuringa JJ; Ossenkoppele G; Vellenga E; Huls G
Haematologica; 2011 Sep; 96(9):1310-7. PubMed ID: 21606167
[TBL] [Abstract][Full Text] [Related]
30. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
Haferlach C; Mecucci C; Schnittger S; Kohlmann A; Mancini M; Cuneo A; Testoni N; Rege-Cambrin G; Santucci A; Vignetti M; Fazi P; Martelli MP; Haferlach T; Falini B
Blood; 2009 Oct; 114(14):3024-32. PubMed ID: 19429869
[TBL] [Abstract][Full Text] [Related]
31. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
32. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
[TBL] [Abstract][Full Text] [Related]
33. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
[TBL] [Abstract][Full Text] [Related]
34. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
35. NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.
Rubio P; Campos B; Digiorge JA; Gallego MS; Medina A; Rossi JG; Felice MS; Alonso CN
Int J Hematol; 2016 Nov; 104(5):582-590. PubMed ID: 27436336
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of low allelic ratio
Sakaguchi M; Yamaguchi H; Najima Y; Usuki K; Ueki T; Oh I; Mori S; Kawata E; Uoshima N; Kobayashi Y; Kako S; Tajika K; Gomi S; Shono K; Kayamori K; Hagihara M; Kanda J; Uchiyama H; Kuroda J; Uchida N; Kubota Y; Kimura S; Kurosawa S; Nakajima N; Marumo A; Omori I; Fujiwara Y; Yui S; Wakita S; Arai K; Kitano T; Kakihana K; Kanda Y; Ohashi K; Fukuda T; Inokuchi K
Blood Adv; 2018 Oct; 2(20):2744-2754. PubMed ID: 30341082
[TBL] [Abstract][Full Text] [Related]
37. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML).
Schneider F; Hoster E; Schneider S; Dufour A; Benthaus T; Kakadia PM; Bohlander SK; Braess J; Heinecke A; Sauerland MC; Berdel WE; Buechner T; Woermann BJ; Feuring-Buske M; Buske C; Creutzig U; Thiede C; Zwaan MC; van den Heuvel-Eibrink MM; Reinhardt D; Hiddemann W; Spiekermann K
Ann Hematol; 2012 Jan; 91(1):9-18. PubMed ID: 21744003
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia.
Schnittger S; Bacher U; Kern W; Alpermann T; Haferlach C; Haferlach T
Leukemia; 2011 Aug; 25(8):1297-304. PubMed ID: 21537333
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
40. ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status.
Hämäläinen M; Juvonen V; Häikiö S; Lakkala T; Johansson J; Pelliniemi TT; Salmi TT; Remes K; Kairisto V
Eur J Haematol; 2010 Oct; 85(4):361-2. PubMed ID: 20546020
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]